Aim: To evaluate the effects of insulin degludec/insulin aspart (IDegAsp) coformulation as an intensification of insulin treatment for glycemic control in patients with type 2 diabetes (T2D) in a long term real-world clinical setting.
Materials And Methods: This retrospective non-interventional study, included 210 patients with T2D who to IDegAsp coformulation from prior insulin treatment in a tertiary endocrinology center between September 2017 and December 2019. The baseline data was taken as the index date and defined as the first IDegAsp prescription claim.
Purpose: This study aimed to examine the life events, emotional health and post-illness awareness of COVID-19 patients. We interviewed 25 people who experienced COVID-19.
Design: The study was executed in qualitative descriptive design.
Background: The aim of the study was to determine the views of patient relatives and health professionals about the reasons of patients enrolled in the community mental health center to discontinue or irregularly continue the center.
Methods: This study is qualitative and phenomenological. The study group consisted of 17 patient relatives and eight health professionals according to the maximum variation sampling method.